PMID- 21789125
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20111110
LR  - 20231104
IS  - 1758-8359 (Electronic)
IS  - 1758-8340 (Print)
IS  - 1758-8340 (Linking)
VI  - 2
IP  - 1
DP  - 2010 Jan
TI  - Targeted therapy for metastatic renal cell carcinoma: current treatment and 
      future directions.
PG  - 39-49
LID - 10.1177/1758834009352498 [doi]
AB  - An understanding of vascular endothelial growth factor (VEGF) and mammalian 
      target of rapamycin (mTOR) pathways has greatly changed the way metastatic renal 
      cell carcinoma (RCC) is treated. Based on available phase III randomized trials, 
      anti-VEGF agents such as sunitinib, sorafenib, bevacizumab-based therapy, and 
      mTOR-targeted agents such as temsirolimus and everolimus have been used in the 
      treatment armamentarium for this disease. Now that agents directed against these 
      pathways have largely replaced immunotherapy as the standard of care, new 
      questions have emerged and are the subject of ongoing clinical trials. The 
      development of new targeted therapies including axitinib, pazopanib, cediranib, 
      volociximab, tivozanib (AV-951), BAY 73-4506, and c-met inhibitors such as 
      GSK1363089 and ARQ197 may potentially expand the list of treatment options. 
      Sequential and combination targeted therapies are currently under investigation 
      in advanced disease as are adjuvant and neo-adjuvant approaches around 
      nephrectomy.
FAU - Heng, Daniel Y C
AU  - Heng DY
AD  - BC Cancer Agency, 600 West 12 Avenue, Vancouver, British Columbia, V5Z 4E6, 
      Canada.
FAU - Kollmannsberger, Christian
AU  - Kollmannsberger C
FAU - Chi, Kim N
AU  - Chi KN
LA  - eng
PT  - Journal Article
PL  - England
TA  - Ther Adv Med Oncol
JT  - Therapeutic advances in medical oncology
JID - 101510808
PMC - PMC3126007
OTO - NOTNLM
OT  - adjuvant
OT  - combination therapy
OT  - mammalian target of rapamycin
OT  - neo-adjuvant
OT  - nonclear cell histologies
OT  - renal cell carcinoma
OT  - vascular endothelial growth factor
EDAT- 2010/01/01 00:00
MHDA- 2010/01/01 00:01
PMCR- 2010/01/01
CRDT- 2011/07/27 06:00
PHST- 2011/07/27 06:00 [entrez]
PHST- 2010/01/01 00:00 [pubmed]
PHST- 2010/01/01 00:01 [medline]
PHST- 2010/01/01 00:00 [pmc-release]
AID - 10.1177_1758834009352498 [pii]
AID - 10.1177/1758834009352498 [doi]
PST - ppublish
SO  - Ther Adv Med Oncol. 2010 Jan;2(1):39-49. doi: 10.1177/1758834009352498.